Patients with polycythemia vera and essential thrombocythemia with prior malignancy do not have significantly worse outcome

Leukemia Research

Volumn 37, Issue 11, 2013, Pages 1472-1476

  Cherry, Mohamad ^a   Cardenas Turanzas, Marylou ^b   Pham, Hannah ^c   Kantarjian, Hagop ^b   Cortes, Jorge ^b   Pierce, Sherry ^b   Zhou, Lingsha ^b   Verstovsek, Srdan ^b  

^a UNIVERSITY OF OKLAHOMA   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c TEXAS TECH UNIVERSITY   (United States)

Author keywords

Essential thrombocythemia; Myeloproliferative disorders; Polycythemia vera; Prior malignancy; Transformation to acute leukemia; Transformation to myelofibrosis

Indexed keywords

JANUS KINASE 2; LACTATE DEHYDROGENASE;

ACUTE LEUKEMIA; ADOLESCENT; ADULT; AGE; AGED; ARTICLE; BLOOD CELL COUNT; CANCER PROGNOSIS; CANCER SURVIVAL; CYTOGENETICS; FEMALE; FOLLOW UP; GENE MUTATION; HEMATOLOGIC MALIGNANCY; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MUTATION RATE; MYELOFIBROSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POLYCYTHEMIA VERA; PREDICTIVE VALUE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THROMBOCYTOPENIA;

ESSENTIAL THROMBOCYTHEMIA; MYELOPROLIFERATIVE DISORDERS; POLYCYTHEMIA VERA; PRIOR MALIGNANCY; TRANSFORMATION TO ACUTE LEUKEMIA; TRANSFORMATION TO MYELOFIBROSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; POLYCYTHEMIA VERA; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; THROMBOCYTHEMIA, ESSENTIAL; YOUNG ADULT;

EID: 84886772830     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.08.002     Document Type: Article

References (16)

1. Berlin N.I. Diagnosis and classification of the polycythemias. Semin Hematol 1975, 12:339-351.
2. Passamonti F., Malabarba L., Orlandi E., Barate C., Canevari A., Brusamolino E., et al. Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia. Haematologica 2003, 88:13-18.
3. Dror Y., Zipursky A., Blanchette V.S. Essential thrombocythemia in children. J Pediatr Hematol Oncol 1999, 21:356-363.
4. Rozman C., Giralt M., Feliu E., Rubio D., Cortes M.T. Life expectancy of patients with chronic nonleukemic myeloproliferative disorders. Cancer 1991, 67:2658-2663.
5. Swerdlow S.H., International Agency for Research on Cancer, World Health Organization WHO classification of tumours of haematopoietic and lymphoid tissues 2008, International Agency for Research on Cancer, Lyon, France. 4th ed.
6. Scott L.M., Tong W., Levine R.L., Scott M.A., Beer P.A., Stratton M.R., et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007, 356:459-468.
7. Acharya J., Westwood N.B., Sawyer B.M., Messinezy M., Burroughs A.K., Mehta A.B., et al. Identification of latent myeloproliferative disease in patients with Budd-Chiari syndrome using X-chromosome inactivation patterns and in vitro erythroid colony formation. Eur J Haematol 1995, 55:315-321.
8. De Stefano V., Teofili L., Leone G., Michiels J.J. Spontaneous erythroid colony formation as the clue to an underlying myeloproliferative disorder in patients with Budd-Chiari syndrome or portal vein thrombosis. Semin Thromb Hemost 1997, 23:411-418.
9. Radaelli F., Onida F., Rossi F.G., Zilioli V.R., Colombi M., Usardi P., et al. Second malignancies in essential thrombocythemia (ET): a retrospective analysis of 331 patients with long-term follow-up from a single institution. Hematology 2008, 13:195-202.
10. Petti M.C., Spadea A., Avvisati G., Spadea T., Latagliata R., Montefusco E., et al. Polycythemia vera treated with pipobroman as single agent: low incidence of secondary leukemia in a cohort of patients observed during 20 years (1971-1991). Leukemia 1998, 12:869-874.
11. Brandt L., Anderson H. Survival and risk of leukaemia in polycythaemia vera and essential thrombocythaemia treated with oral radiophosphorus: are safer drugs available. Eur J Haematol 1995, 54:21-26.
12. Randi M.L., Fabris F., Girolami A. Second malignancies in patients with essential thrombocythaemia. Br J Haematol 2002, 116:923-924.
13. Siegel R., DeSantis C., Virgo K., Stein K., Mariotto A., Smith T., et al. Cancer treatment and survivorship statistics. CA Cancer J Clin 2012, 62:220-241.
14. Xin C.H., Xu J.Q., Sui J.R., Wang X.L. Analysis on 71 patients with polycythemia vera. Zhongguo shi yan xue ye xue za zhi/Zhongguo bing li sheng li xue hui 2012, 20:667-670.
15. Mazzotta S., Guerranti R., Gozzetti A., Bucalossi A., Bocchia M., Sammassimo S., et al. Increased serum lactate dehydrogenase isoenzymes in Ph-negative chronic myeloproliferative diseases: a metabolic adaptation. Hematology 2006, 11:239-244.
16. Anger B., Haug U., Seidler R., Heimpel H. Polycythemia vera: a clinical study of 141 patients. Blut 1989, 59:493-500.